Park Avenue Securities LLC acquired a new position in shares of Biogen Inc (NASDAQ:BIIB) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 626 shares of the biotechnology company’s stock, valued at approximately $221,000.
Other institutional investors also recently made changes to their positions in the company. LeJeune Puetz Investment Counsel LLC bought a new stake in shares of Biogen during the 3rd quarter worth approximately $107,000. Adviser Investments LLC raised its stake in shares of Biogen by 745.7% during the 2nd quarter. Adviser Investments LLC now owns 389 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 343 shares in the last quarter. NEXT Financial Group Inc bought a new stake in shares of Biogen during the 3rd quarter worth approximately $133,000. Harvest Fund Management Co. Ltd raised its stake in shares of Biogen by 122.0% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 384 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 211 shares in the last quarter. Finally, Kaizen Advisory LLC raised its stake in shares of Biogen by 145.8% during the 2nd quarter. Kaizen Advisory LLC now owns 499 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 296 shares in the last quarter. Institutional investors own 87.55% of the company’s stock.
BIIB opened at $325.20 on Friday. Biogen Inc has a 1-year low of $249.17 and a 1-year high of $388.67. The company has a current ratio of 2.75, a quick ratio of 2.46 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $66.79 billion, a P/E ratio of 14.91, a price-to-earnings-growth ratio of 1.31 and a beta of 1.01.
In other Biogen news, EVP Michael D. Ehlers sold 1,000 shares of the company’s stock in a transaction on Wednesday, September 26th. The stock was sold at an average price of $350.00, for a total value of $350,000.00. Following the transaction, the executive vice president now directly owns 4,281 shares of the company’s stock, valued at approximately $1,498,350. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.29% of the company’s stock.
A number of brokerages have recently issued reports on BIIB. Citigroup dropped their price objective on Biogen from $483.00 to $470.00 and set a “buy” rating on the stock in a research note on Monday, October 8th. BidaskClub cut Biogen from a “buy” rating to a “hold” rating in a research note on Friday, October 19th. Barclays upped their price objective on Biogen from $295.00 to $320.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 25th. ValuEngine upgraded Biogen from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Oppenheimer set a $380.00 price target on Biogen and gave the company a “buy” rating in a research note on Sunday, October 28th. Nine research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $383.01.
COPYRIGHT VIOLATION WARNING: “Park Avenue Securities LLC Takes Position in Biogen Inc (BIIB)” was posted by BBNS and is the property of of BBNS. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/11/10/park-avenue-securities-llc-takes-position-in-biogen-inc-biib/2972288.html.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.
See Also: What is a bull market?
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.